Transformed Indolent B-cell Non-hodgkin Lymphoma to Diffuse Large B-cell Lymphoma

• CLINICAL_TRIALS research · 2026-04-13
  Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas [Phase 2, Phase 3]

  A Phase 2/Phase 3 trial is evaluating adding venetoclax to standard chemotherapy for high-grade B-cell lymphomas, including diffuse large B-…

• CLINICAL_TRIALS research · 2026-02-27
  Clinical Trial Update: CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma [Phase 1]

  Phase 1 trial evaluating CC-99282 in combination with Rituximab given early after CAR T therapy in patients with relapsed or refractory B-ce…

• CLINICAL_TRIALS trial_result · 2026-02-27
  Clinical Trial Update: Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma [Phase 1]

  Phase 1 clinical trial update for tegavivint in relapsed or refractory diffuse large B-cell lymphoma, with ongoing recruitment.

• CLINICAL_TRIALS research · 2024-09-26
  Clinical Trial Update: Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy [Phase 2]

  Phase 2 clinical trial evaluating epcoritamab versus observation in B-cell lymphoma patients not in complete remission after CD19-directed C…